Pravastatin + Fenofibrate + Metformin + Orlistat + Irbesartan

This is a combination of five different medications, each with distinct mechanisms of action: 1. **Pravastatin** - An HMG-CoA reductase inhibitor (statin) that lowers LDL cholesterol 2. **Fenofibrate** - A fibric acid derivative that primarily reduces triglycerides and increases HDL cholesterol 3. **Metformin** - An oral antidiabetic medication that improves insulin sensitivity 4. **Orlistat** - A lipase inhibitor that reduces dietary fat absorption 5. **Irbesartan** - An angiotensin II receptor antagonist used for hypertension (not mentioned in the search results) ## Combination Therapies The search results provide information about several combinations: - **Fenofibrate + Orlistat**: This combination has been studied for treating obesity and metabolic syndrome. Combined treatment further improves metabolic parameters in overweight/obese patients with metabolic syndrome[1][4]. - **Metformin + Orlistat**: This combination has been patented for treating obesity. The effective dosage for orlistat is 50-1440 mg/day (preferably 120-360 mg/day) and for metformin is 100-3000 mg/day (preferably 500-2550 mg/day)[3]. - **Pravastatin + Fenofibrate**: A fixed-dose combination called Pravafenix® (pravastatin 40 mg + fenofibrate 160 mg) has been developed for patients with mixed hyperlipidemia[8][10]. ## Mechanisms of Action Each component has a distinct mechanism: - **Pravastatin**: Inhibits HMG-CoA reductase, reducing cholesterol synthesis - **Fenofibrate**: PPARα agonist that lowers triglyceride-rich lipoproteins, raises HDL levels, and has variable effects on LDL levels[3][5] - **Metformin**: Improves insulin sensitivity and reduces hepatic glucose production - **Orlistat**: Inhibits gastrointestinal lipases, reducing dietary fat absorption - **Irbesartan**: Blocks angiotensin II receptors, causing vasodilation ## Clinical Evidence While there is evidence for some of these drugs in combination, the search results do not mention all five medications used together: - Fenofibrate + orlistat combination appears to be safe and may further improve metabolic parameters in overweight/obese patients with metabolic syndrome[2][5]. - Pravastatin + fenofibrate (Pravafenix) has been studied in clinical trials for up to 64 weeks and appears to be well-tolerated with no reports of myopathy or rhabdomyolysis[6][8]. - Metformin + orlistat combination has been patented, though one study indicated that adding metformin did not result in significant additional effects on weight loss and insulin resistance compared to orlistat alone[9]. ## Dosing Information Based on the search results: - Orlistat: 50-1440 mg/day (preferably 120-360 mg/day) - Metformin: 100-3000 mg/day (preferably 500-2550 mg/day) - Pravafenix: Fixed-dose combination of pravastatin 40 mg and fenofibrate 160 mg ## Safety Considerations - The pravastatin + fenofibrate combination has been evaluated for safety in clinical trials and appears to be well-tolerated[6][8]. - When combining fibrates with statins, there is a theoretical increased risk of myopathy, though this was not observed in clinical trials of Pravafenix[6]. - Fenofibrate may cause decreased creatinine clearance in some patients[6].